Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-1517

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-1517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 1517 9

68071 1517 9
This is a product label for Losartan Potassium 50mg tablets manufactured by uCare Pharmaceuticals. It includes information such as the NDC number, lot number, and expiration date. The label also provides a warning to keep the medicine out of reach of children and to store it at a controlled temperature. It advises consumers to call their doctor for medical advice about side effects and provides the number for the FDA to report any side effects.*
FDA Label Image

Structural Formula (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 01)

FDA Label Image

Figure 1 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 02)

Figure 1 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 02)
The text suggests a comparison between two medications, Atenolol and Osartan Potassium, in terms of reducing the risk of primary endpoint in patients. The study records the percentage of risk reduction in patients who were administered these drugs and the adjusted risk reduction percentage with its corresponding p-value. The study was conducted over a period of 66 months, with a record of the primary endpoint at regular intervals of every 6 months.*
FDA Label Image

Figure 2 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 03)

Figure 2 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 03)
This is a report presenting the percentage of patients with fatal/non-fatal stroke during a study that involved the use of Atenolol and Losartan Potassium. The adjusted risk reduction was 25% with a p-value of 0.001. The report also includes 12 months of data.*
FDA Label Image

Figure 3 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 04)

FDA Label Image

Losartan (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.